Ratings Fortis Healthcare Limited

Equities

Delayed NSE India S.E. Other stock markets 03:49:30 16/09/2024 pm IST			5-day change	1st Jan Change
596.85 ^INR	+2.17%		+9.26%	+42.38%

22/08	IHH Healthcare Updates on Tokyo Court Case Over Fortis Acquisition	MT
08/08	Jefferies Adjusts Fortis Healthcare's Price Target to INR575 From INR545, Keeps at Buy	MT

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.

Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 46% by 2027.
The company's profit outlook over the next few years is a strong asset.
The company is in a robust financial situation considering its net cash and margin position.
Analysts covering this company mostly recommend stock overweighting or purchase.
Over the past four months, analysts' average price target has been revised upwards significantly.
Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.

The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 55.11 times its estimated earnings per share for the ongoing year.
Based on current prices, the company has particularly high valuation levels.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The valuation of the company is particularly high given the cash flows generated by its activity.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
Over the past twelve months, analysts' opinions have been revised negatively.

Source: Surperformance

Source: Refinitiv

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Composite Valuation	Capi. ($)
FORTIS HEALTHCARE LIMITED		5.26B
BANGKOK DUSIT MEDICAL SERVICES		13.99B
IHH HEALTHCARE		13.88B
AIER EYE HOSPITAL GROUP CO., LTD.		12.23B
APOLLO HOSPITALS ENTERPRISE LIMITED		12.03B
ENCOMPASS HEALTH CORPORATION		9.38B
THE ENSIGN GROUP, INC.	-	8.66B
RAMSAY HEALTH CARE LIMITED		6.27B
MOUWASAT MEDICAL SERVICES COMPANY		5.47B
DALLAH HEALTHCARE COMPANY		4.18B
Average		9.13B
Weighted average by Cap.